Karin Kogermann

Dr. K. Kogermann is a pharmacist specialized in pharmaceutical technology and physical pharmacy. She received her master degree at the University of Tartu (UT). She completed her PhD at the University of Helsinki, Finland in 2008 entitled: „Understanding solid-state transformations during dehydration: new insights using vibrational spectroscopy and multivariate modeling“. After the defense she continued her scientific career at the UT. In 2012 she received a Mobilitas Postdoctoral Research Fellow grant and continued her studies in the field of biotechnology at the Institute of Technology, Prof T. Tenson Antibiotics Laboratory (UT). The main aim of her postdoctoral research was to develop in vitro and in vivo infection models in mice and understand the action mechanisms of antibiotics. Currently she is working as an Associate Professor and has her research laboratory/group at the Institute of Pharmacy.

K. Kogermann has been acting as a grant holder/principal investigator in several Estonian Research Council projects. Her research interests include the physical pharmacy and solid state analysis-related (poorly water-soluble drugs; electrospun/3D printed drug delivery systems, amorphous solid dispersions, process induced transformations and process analytical tehnology) as well as infection and antibacterial therapy-related topics (infection models, action mechanisms of antibiotics). Her present research is focused on combining these two branches and develop antimicrobial nanostructured biomaterials as controlled drug delivery systems for effective wound care (skin wounds and oral wounds) and investigation of their performance. The main goal is to understand the effects of the solid-state, mechanical and technological properties on the bioactivity of wound matrices and reveal their structure-activity relationships. In parallel, novel wound infection models are developed.

She has (co-)authored 49 original peer-reviewed research publications and more than 190 conference proceedings. She has written two scientific textbook chapters (in English) and 2 popular-scientific books (in Estonian). She has supervised 5 PhD students and currently is supervising 9 PhD students. K. Kogermann is acting as an expert at the European Pharmacopoeia Commission Expert Group G12 and Estonian State Agency of Medicine. She has been given an international and national research awards and she is a member of Estonian Acadamical Society of Pharmacy and Estonian Young Academy of Sciences.

CAREER BREAKS: 2008 (June) - 2010 (September) Maternity leave; 2011 (October) - 2012 (August) Maternity leave; 2020 (October) – 2022 (January) Maternity leave

CV (ETIS): https://www.etis.ee/CV/Karin_Kogermann/est?tabId=CV_ENG

Publications (ETIS): https://www.etis.ee/Portal/Persons/Display/4bf814ee-e8a1-48e9-a9bc-253bf8f71d83?

Research publications (Researchgate): https://www.researchgate.net/profile/Karin_Kogermann

CURRENT RESEARCH PROJECT: Development of biorelevant assays for the analyses of multifunctional antimicrobial wound dressings for the treatment of wound infections (PRG1507); (1.01.2022−31.12.2026), Grant holder/principal investigator: K. Kogermann. Estonian Research Council. TU, Faculty of Medicine.

COMPLETED RESEARCH PROJECTS

(1) Development of multifunctional antimicrobial peptides releasing drug delivery systems for the prevention and treatment of skin and wound infections (PRG726); (1.01.2020−31.03.2021); Grant holder/principal investigator: K. Kogermann. Estonian Research Council. TU, Faculty of Medicine.

(2) Design and Development of Multicomponent Antibacterial Nanofibrous Dressings for Advanced Wound Care (PUT1088); (1.01.2016−31.12.2019), Grant holder/principal investigator; K. Kogermann. Estonian Research Council. TU, Faculty of Medicine.

(3) IUT34-18 "Multifunctional nanomedicines – design and quality assessment (1.01.2015−01.01.2016)". Principal investigator: K. Kogermann; 2016-2020 (investigator), TU, Faculty of Medicine, Estonian Research Council.

(4) ETF7980 "Solid state properties of pharmaceutical substances and their modification possibilities (1.09.2010−31.08.2016)". Grant holder/principal investigator: K. Kogermann, TU, Faculty of Medicine; Estonian Research Council.

(5) MJD321 "Effects of macrolide antibiotics on bacterial physiology- cell filamentation (1.08.2012−31.07.2015)", Mobilitas Post-Doctoral Research Fellow, TU, Faculty of Science and Technology, Institute of Technology;

(6) SF0180042s09 "Solid state properties of pharmaceuticals and their modification possibilities (1.01.2009−31.12.2014)", P. Veski/K. Kogermann Grant holder/principal investigator, TU, Faculty of Medicine; Estonian Research Council.

CURRENT APPLIED RESEARCH and ANALYSES SERVICE PROJECT:

Service project Chemipharm AS, „Development and testing of nasal spray consisting bovine colostrum derived antibodies against SARS-CoV-2“, 26.01.2021- 31.12.2022, (Grant holder/principal investigator: K. Kogermann at the University of Tartu), University of Tartu, Faculty of Medicine, Institute of Pharmacy. Related with the consortium agreement between 5 partners (University of Tartu, Estonian University of Life Sciences, Icosagen AS, Chemipharm AS, Teadus ja Tegu OÜ), 2020. One of the principal investigators at the University of Tartu: K. Kogermann.

COMPLETED APPLIED RESEARCH and ANALYSES SERVICE PROJECTS:

(1) Procurement project no 217903 "The suitability of fish and shellfish materials for electrospinning of fibrous wound scaffolds", 30.03.2020 - 30.11.2021, University of Tartu, Faculty of Medicine, Institute of Pharmacy (Grant holder/principal investigator: K. Kogermann at the University of Tartu), Estonian University of Life Sciences/Agricultural Registers and Information Board, PRIA

(2) Service project LMVFA19397 "In vitro dissolution testing- comparative study between brand and generic veterinary drug product (6.05.2019−21.06.2019)", (Grant holder/principal investigator: K. Kogermann), University of Tartu, Faculty of Medicine, Institute of Pharmacy. Interchemie Werken De Adelaar Estonia AS.

(3) TEKES projekt "TUTL -projekti 6767/31/17, Acouspin IntelliPatch" ("TUTL -projekti 6767/31/17, Acouspin IntelliPatch"), 01.01.2018 - 30.06.2019, University of Helsinki, University of Tartu (principal investigator; K. Kogermann), TEKES.

MAJOR COLLABORATIONS: Estonian Universities: Synthetic Biology Center of Excellence, Institute of Technology, UT (Prof T. Tenson; Dr M. Purtinš, Prof M. Pooga); Department of Geology, UT (Prof K. Kirsimäe; Dr P. Paiste; J. Aruväli); Institute of Chemistry, UT (Prof E. Lust; Dr T. Roman); Institute of Physics, UT (Dr V. Kisand; Dr I. Jõgi); Dermatology Clinic of Tartu University Hospital (Prof Dr K. Kingo); Institute of Dentistry, UT (Dr Ü. Voog-Oras), Estonian University of Life Sciences, Dr A. Kisand.

Estonian Companies: Chemipharm AS (Dr Ruth Oltjer), Icosagen AS (Prof M. Ustav), Gelatex OÜ (Dr M.-E. Martens).

International collaborators: Faculty of Pharmaceutical Sciences and LEO Foundation Center for Cutaneous Drug Delivery, Department of Pharmacy, University of Copenhagen (Dr J. Østergaard); Faculty of Pharmacy University of Ljubljana (Prof J. Kristl); Department of Physics, University of Helsinki (Prof E. Haeggström); Drug Transport and Delivery Research Group, Department of Pharmacy, UiT The Arctic University of Norway, Norway (Prof N. Skalko-Basnet, Dr A.M. Holsæter). Recently initiated collaborations: Institute of Pharmaceutical Sciece, King´s College London (Dr J. Mason); National Infection Service, Public Health England (Dr M. Sutton); Institute of Fundamental Technological Research, Polish Academy of Sciences (Dr F. Pierini, Dr P. Korczyk, Dr T. Kowalczyk).

International company: Stellenbosch Nanofiber Company (Dr E. Smit);